Nuplazid Suppresses Esophageal Squamous Cell Carcinoma Growth in Vitro and in Vivo by Targeting PAK4
Overview
Authors
Affiliations
Background: Due to the high recurrence and low 5-year survival rates of esophageal squamous cell carcinoma (ESCC) after treatment, the discovery of novel drugs for recurrence chemoprevention is of particular importance.
Methods: We screened the FDA-approved drug library and found that Nuplazid, an atypical antipsychotic that acts as an effective 5-HT 2 A receptor inverse agonist, could potentially exert anticancer effects in vitro and in vivo on ESCC.
Results: Pull-down results indicated that Nuplazid binds with p21-activated kinase 4 (PAK4), and a kinase assay showed that Nuplazid strongly suppressed PAK4 kinase activity. Moreover, Nuplazid exhibited inhibitory effects on ESCC in vivo.
Conclusions: Our findings indicate that Nuplazid can suppress ESCC progression through targeting PAK4.
Zhang J, Wu Q, Xie Y, Li F, Wei H, Jiang Y Acta Pharm Sin B. 2024; 14(10):4329-4344.
PMID: 39525580 PMC: 11544187. DOI: 10.1016/j.apsb.2024.07.022.
Yuan Q, Shi Y, Zhang Y, Shi Y, Hussain Z, Zhao J Cancer Cell Int. 2024; 24(1):114.
PMID: 38528618 PMC: 10964662. DOI: 10.1186/s12935-024-03291-8.
Wu W, Xu J, Gao D, Xie Z, Chen W, Li W Cell Death Dis. 2023; 14(6):364.
PMID: 37328464 PMC: 10276051. DOI: 10.1038/s41419-023-05883-0.
Li M, Duan L, Wu W, Li W, Zhao L, Li A Oncogenesis. 2023; 12(1):24.
PMID: 37147297 PMC: 10163056. DOI: 10.1038/s41389-023-00472-4.
Liu Y, Sun X, Liu J, Liu W, Jin J, Liu Y Bull Exp Biol Med. 2023; 174(4):478-481.
PMID: 36899200 DOI: 10.1007/s10517-023-05733-1.